Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPONSoR study of spironolactone for maintenance of sinus rhythm in hypertensive patients with atrial fibrillation and preserved left ventricular ejection fraction
2020-005484-31Phase 3Active
- Sponsor
- CHU Caen Normandie
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of spironolactone in Atrial fibrillation (AFib) and hypertension (HTN) (2 arms), sponsored by CHU Caen Normandie. Primary endpoint: First documented recurrence of atrial fibrillation within 12 months. Started Jul 2022; status: active.
02
Drugs
spironolactone
03
Conditions
Atrial fibrillation (AFib)hypertension (HTN)
Beyond the preview
Go deeper on 2020-005484-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005484-31.